ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Director, Global Pre-Approval Patient Access at Revolution Medicines - ApplyBlast

Director, Global Pre-Approval Patient Access

Revolution Medicines

5 months ago

3.5 on Glassdoor

Onsite

Full Time

Senior

1 applicant

View Job Listing

Apply to 100+ jobs

About this role

The Director of Global Pre-Approval Patient Access leads the strategy, design, and execution of global early access programs for Revolution Medicines' pipeline, ensuring appropriate patient access to investigational therapies targeting RAS-addicted cancers while aligning with clinical, regulatory, and company priorities.

Responsibilities

Develop and support global early access strategy aligned with clinical and regulatory milestones
Design and implement free of charge named-patient and cohort early access programs globally
Serve as overall cross-functional leader of the programs, liaising across Clinical, Regulatory, Medical Affairs, Commercial, Legal, Supply Chain
Establish governance for global evaluation and prioritization of potential new programs
Oversee program operations, including vendors

Skills

Qualifications

Bachelor's degree in healthcare field with advanced degree preferredMinimum of 8 years of clinical trial operations and Oncology EA experience in a biotech/pharmaceutical company

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.